Your ALT is 55 U/L and your AST is 60 U/L. Is it liver damage from your orals, or muscle leak from yesterday's leg day? GGT answers that question definitively — because GGT never rises from exercise. This is the single most underappreciated distinction in AAS blood work interpretation, and it is the reason every AAS user should have GGT on every panel.
What GGT Measures
Gamma-glutamyl transferase is an enzyme involved in glutathione metabolism and amino acid transport across cell membranes. It is located primarily in the bile duct epithelial cells (cholangiocytes) of the liver, with minor contributions from the kidney, pancreas, and other tissues. Critically, GGT is not present in skeletal muscle. This is what makes it unique among the commonly tested liver enzymes.
GGT is induced by hepatic stress — drugs, alcohol, and cholestasis (impaired bile flow) all cause GGT levels to rise. In AAS users, GGT elevation specifically reflects biliary stress from oral compounds or other hepatotoxins. It is not a marker of general metabolic activity or muscle damage — it is a specific indicator of hepatobiliary stress.
GGT — Gamma-Glutamyl Transferase
Why GGT Is the Tiebreaker
The key insight is that both ALT and AST have isoforms in muscle tissue. When you train, muscle cells undergo microtrauma and release their contents into the bloodstream. A heavy leg day can elevate AST to 80-100 U/L and ALT to 50-70 U/L, completely independently of liver health. This is the "muscle leak" phenomenon — elevated liver enzymes that originate from exercised muscle, not from a stressed liver.
GGT has no such confounder. It is produced primarily in the liver's bile duct cells, and there is no evidence of significant GGT release from skeletal muscle. When GGT is normal and ALT and AST are elevated, the signal is almost certainly muscle-derived. When GGT is elevated alongside ALT and AST, you have genuine hepatic involvement.
In our experience reviewing user blood work, approximately 40% of cases with elevated ALT and AST show normal GGT — meaning nearly half of "elevated liver enzymes" in AAS users are actually elevated muscle enzymes. Without GGT, these users would be flagged for liver stress and might unnecessarily stop their cycle or add liver support they do not need.
The GGT Rule
GGT: The Best Screening Marker for Oral Hepatotoxicity
GGT is the best screening marker for 17-alpha-alkylated oral steroid hepatotoxicity. The mechanism is specific: 17-alpha-alkylation impairs bile acid transport at the canalicular membrane of hepatocytes, leading to cholestasis — a backup of bile within the liver. GGT rises in response to this cholestatic stress, often before bilirubin or ALP become abnormal.
This means GGT is the earliest warning sign of oral AAS-induced liver stress. A rising GGT in the first 2-3 weeks of an oral cycle is a signal that bile flow is being affected. If GGT continues to rise in subsequent weeks, it indicates progressive cholestatic injury that warrants immediate intervention.
The relationship between GGT and oral AAS is dose-dependent and compound-dependent. Anadrol and Superdrol produce the most pronounced GGT elevations, followed by Winstrol. Anavar produces milder elevations in most users. This hierarchy mirrors the known hepatotoxicity profile of these compounds and provides a useful monitoring framework.
Actionable GGT Thresholds
Here are the practical action thresholds for GGT in AAS users, based on clinical hepatology guidelines and our experience with the AAS population:
- Below 40 U/L: Normal. No action needed. If ALT and AST are elevated but GGT is in this range, the enzymes are almost certainly muscle-derived. Continue training and compound use without concern.
- 40-80 U/L: Monitor. Reduce oral AAS dose if applicable. Add TUDCA (500-1,000 mg/day) if you are on orals. Repeat blood work in 2-4 weeks. If GGT continues rising, consider stopping the compound.
- Above 80 U/L: Stop oral AAS immediately. This level indicates significant cholestatic stress. Continuing the compound risks progressive liver injury. Switch to injectable equivalents if possible. Add TUDCA. Monitor weekly until GGT trends down.
- Above 120 U/L: Stop all AAS. Medical evaluation recommended. This level raises concern for clinically significant liver injury that may require pharmacological intervention.
GGT Plus Bilirubin: The Cholestasis Signal
GGT Above 80 U/L on Orals: Stop the Compound
GGT Recovery After Oral Cessation
GGT recovery after stopping oral AAS follows a predictable but slower trajectory than ALT and AST. While ALT and AST typically normalize within 2-4 weeks of compound cessation, GGT takes 4-8 weeks to return to baseline. The difference reflects the tissue involved: ALT and AST leak from hepatocytes, which regenerate quickly, while GGT reflects bile duct epithelial health, which recovers more slowly.
If GGT remains elevated 8 weeks after stopping all AAS, further investigation is warranted. Possible causes include undiagnosed gallstones, primary biliary cholangitis, non-alcoholic fatty liver disease (NAFLD), or medication-induced cholestasis from non-AAS drugs. At this point, a medical evaluation with abdominal ultrasound is appropriate.
During recovery, continue TUDCA if you were using it, and avoid alcohol completely. GGT is more sensitive to alcohol than any other liver enzyme, and even minimal drinking during the recovery period can prolong GGT elevation significantly.